EGFR and non-small cell lung carcinoma: Therefore, our meta-analysis provides more precise and valid comparisons, and presents a comprehensive evaluation of the efficacy and safety of erlotinib-plus-bevacizumab combination compared to erlotinib monotherapy in patients with advanced EGFR-positive NSCLC.